Biopharmaceuticals
Tiburio is dedicated to developing transformative treatments for rare endocrine diseases. The company is advancing two dopamine somatostatin chimeric compounds. TBR-760 has the potential to be the first and only drug treatment for nonfunctioning pituitary adenomas. TBR-065 is a dopamine somatostatin chimeric compound that has been evaluated in a phase I clinical trial, for which Tiburio is currently exploring appropriate rare endocrine indications.
Abraham N. Ceesay
Nice Insight/That’s Nice
89 Fifth AvenueFifth FloorNew YorkNY 10003-3020
New York – San Diego – ChicagoLondon – Frankfurt – Shanghai
Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.